Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Graeff

Showing results (161-170 of 206) with videos related to

Pageof 21
Sort By:
International Journal of Oncology|May 12, 2011
Expression of urokinase-type plasminogen-activator (upa) and its receptor (upar) in human ovarian-cancer cells and in-vitro invasion capacityC Will, O Wilhelm, S Hohl, et al.
The American Journal of Pathology|April 1, 1997
Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissueT Luther, V Magdolen, S Albrecht, et al.
Geburtshilfe Und Frauenheilkunde|July 1, 1988
[Puerperal ovarian vein thrombophlebitis--a rare puerperal complication]W Loos, R von Hugo, W Rath, et al.
International Journal of Oncology|May 17, 2011
Urokinase-type plasminogen-activator (upa), a protease with cytokine-like activity in human hl-60 leukemic-cell lineW Berdel, O Wilhelm, M Schmitt, et al.
Geburtshilfe Und Frauenheilkunde|July 1, 1988
[Genital infections and the course of pregnancy: a prospective study]F Fischbach, M Kolben, R Thurmayr, et al.
Seminars in Thrombosis and Hemostasis|July 1, 1991
Fluorescent probes as tools to assess the receptor for the urokinase-type plasminogen activator on tumor cellsM Schmitt, N Chucholowski, E Busch, et al.
Breast Cancer Research and Treatment|July 29, 1999
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapseN Harbeck, C Thomssen, U Berger, et al.
Cancer|December 18, 2001
Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinomaW Kuhn, S Rutke, K Späthe, et al.
Histopathology|June 10, 2000
Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridizationR Hildenbrand, M Leitz, V Magdolen, et al.
Molecular and Cellular Biology|March 10, 2001
beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoterS Hapke, M Gawaz, K Dehne, et al.
Pageof 21

Showing results (161-170 of 206) with videos related to

Sort By:
Pageof 21
International Journal of Oncology|May 12, 2011
Expression of urokinase-type plasminogen-activator (upa) and its receptor (upar) in human ovarian-cancer cells and in-vitro invasion capacityC Will, O Wilhelm, S Hohl, et al.
The American Journal of Pathology|April 1, 1997
Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissueT Luther, V Magdolen, S Albrecht, et al.
Geburtshilfe Und Frauenheilkunde|July 1, 1988
[Puerperal ovarian vein thrombophlebitis--a rare puerperal complication]W Loos, R von Hugo, W Rath, et al.
International Journal of Oncology|May 17, 2011
Urokinase-type plasminogen-activator (upa), a protease with cytokine-like activity in human hl-60 leukemic-cell lineW Berdel, O Wilhelm, M Schmitt, et al.
Geburtshilfe Und Frauenheilkunde|July 1, 1988
[Genital infections and the course of pregnancy: a prospective study]F Fischbach, M Kolben, R Thurmayr, et al.
Seminars in Thrombosis and Hemostasis|July 1, 1991
Fluorescent probes as tools to assess the receptor for the urokinase-type plasminogen activator on tumor cellsM Schmitt, N Chucholowski, E Busch, et al.
Breast Cancer Research and Treatment|July 29, 1999
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapseN Harbeck, C Thomssen, U Berger, et al.
Cancer|December 18, 2001
Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinomaW Kuhn, S Rutke, K Späthe, et al.
Histopathology|June 10, 2000
Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridizationR Hildenbrand, M Leitz, V Magdolen, et al.
Molecular and Cellular Biology|March 10, 2001
beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoterS Hapke, M Gawaz, K Dehne, et al.
Pageof 21